Literature DB >> 21561391

Effect of a low molecular weight, high-purity β-glucan on in vitro digestion and glycemic response.

Pariyarath Sangeetha Thondre1, Christiani Jeya Kumar Henry.   

Abstract

β-Glucans are believed to lower postprandial glycemia due to their ability to increase viscosity and slow down gastric emptying. The effect of high-purity barley β-glucan (Glucagel) was tested on in vitro starch digestibility and glycemic response of chapattis. In a randomized controlled crossover trial, 10 healthy human subjects consumed chapattis containing 0, 4 and 8% β-glucan on different occasions. Capillary blood samples were collected before and at 0, 15, 30, 45, 60, 90 and 120 min after consuming the chapattis. There was no significant difference either in the amount of glucose released after in vitro digestion or in the glycemic response to chapattis with 0, 4 and 8% β-glucan (P>0.05). It may be concluded that low molecular weight barley β-glucan, although of 75% purity, was not effective in lowering glycemic response possibly due to its inability to influence starch digestion and particle breakdown during in vitro digestion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561391     DOI: 10.3109/09637486.2011.566849

Source DB:  PubMed          Journal:  Int J Food Sci Nutr        ISSN: 0963-7486            Impact factor:   3.833


  2 in total

1.  Lentinula edodes mushroom as an ingredient to enhance the nutritional and functional properties of cereal bars.

Authors:  Sara Rosicler Vieira Spim; Nathalia Roberta Cardoso Mendes Castanho; Ana Maria Holtz Pistila; Angela Faustino Jozala; José Martins Oliveira Júnior; Denise Grotto
Journal:  J Food Sci Technol       Date:  2020-07-16       Impact factor: 2.701

2.  Insoluble fiber in young barley leaf suppresses the increment of postprandial blood glucose level by increasing the digesta viscosity.

Authors:  Akira Takano; Tomoyasu Kamiya; Hiroshi Tomozawa; Shiori Ueno; Masahito Tsubata; Motoya Ikeguchi; Kinya Takagaki; Ayaka Okushima; Yu Miyata; Shizuka Tamaru; Kazunari Tanaka; Toru Takahashi
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-24       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.